MCID: TXC002
MIFTS: 52

Toxic Encephalopathy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxic Encephalopathy

MalaCards integrated aliases for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 52 15 17 32
Neurotoxicity Syndromes 74 52 43
Neurotoxicity 12 53 15
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 43 D020258
NCIt 49 C27961
SNOMED-CT 67 19466003
ICD10 32 G92
UMLS 71 C0235032

Summaries for Toxic Encephalopathy

NINDS : 53 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity syndromes, is related to phenylketonuria and alzheimer disease. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian entrainment. The drugs Cycloserine and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 74 Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 911)
# Related Disease Score Top Affiliating Genes
1 phenylketonuria 33.1 TH SLC6A3 MAOB ACHE
2 alzheimer disease 32.9 TH SLC6A3 SERPINA3 PSEN1 NGF MAOB
3 alzheimer disease 2 32.7 SERPINA3 PSEN1 APP
4 neuroblastoma 31.9 TH PSEN1 NGF HMOX1 GFAP CASP3
5 adrenal gland pheochromocytoma 31.8 NGF BDNF
6 prion disease 31.7 SERPINA3 PSEN1 MIR9-1 GFAP APP AIF1
7 sensory peripheral neuropathy 31.7 NGF BDNF ABCB1
8 traumatic brain injury 31.6 GFAP CASP3 BDNF
9 huntington disease 31.5 TH SLC6A3 PSEN1 NGF MAOB GRIN2B
10 brain injury 31.4 GFAP CASP3 BDNF
11 scrapie 31.4 SERPINA3 MIR9-1 GFAP APP ACHE
12 fetal alcohol syndrome 31.4 MIR9-1 H2AC18 GRIN2B GFAP CASP3 BDNF
13 amyotrophic lateral sclerosis 1 31.4 TH SLC6A3 SERPINA3 PSEN1 NGF MIR9-1
14 spinal cord injury 31.4 GFAP CASP3 BDNF
15 ischemia 31.3 HMOX1 GFAP CASP3 BDNF APP
16 fetal alcohol spectrum disorder 31.2 MIR9-1 H2AC18 GRIN2B CASP3 BDNF
17 alcohol dependence 31.2 TH SLC6A3 NGF MAOB GRIN2B BDNF
18 amnestic disorder 31.1 PSEN1 GRIN2B BDNF APP ACHE
19 optic nerve disease 31.1 SERPINA3 GFAP BDNF AIF1
20 parkinson disease, late-onset 31.1 TH SLC6A3 SERPINA3 PSEN1 NGF MIR9-1
21 attention deficit-hyperactivity disorder 31.0 TH SLC6A3 NGF MAOB GRIN2B BDNF
22 substance abuse 31.0 SLC6A3 SERPINA3 H2AC18 BDNF
23 stroke, ischemic 31.0 TH SERPINA3 PSEN1 CASP3 BDNF AIF1
24 wernicke-korsakoff syndrome 31.0 SERPINA3 NGF BDNF ACHE
25 mood disorder 31.0 TH SLC6A3 MAOB H2AC18 GFAP BDNF
26 temporal lobe epilepsy 31.0 GRIN2B GFAP BDNF ABCB1
27 autosomal dominant cerebellar ataxia 30.9 SERPINA3 MIR9-1 H2AC18 APP
28 mental depression 30.9 SLC6A3 SERPINA3 MIR9-1 H2AC18 GRIN2B BDNF
29 nervous system disease 30.9 SERPINA3 PSEN1 NGF MIR9-1 H2AC18 BDNF
30 creutzfeldt-jakob disease 30.8 SLC6A3 SERPINA3 NGF GFAP BDNF APP
31 sleep disorder 30.8 TH SLC6A3 BDNF
32 dystonia 30.8 TH SLC6A3 MAOB GRIN2B BDNF
33 frontotemporal dementia 30.8 PSEN1 GFAP APP ACHE
34 alcohol use disorder 30.8 SLC6A3 H2AC18 GRIN2B BDNF
35 major depressive disorder 30.8 SLC6A3 NGF MAOB GRIN2B BDNF ABCB1
36 pure autonomic failure 30.7 TH MAOB ACHE
37 autism 30.7 TH SLC6A3 NGF MAOB GSTM1 GRIN2B
38 fatal familial insomnia 30.7 SERPINA3 GFAP APP
39 multiple system atrophy 1 30.7 TH SLC6A3 SERPINA3 MAOB GFAP
40 leukemia, acute myeloid 30.7 SERPINA3 MIR9-1 H2AC18 CASP3 ABCG2 ABCB1
41 status epilepticus 30.7 GRIN2B GFAP CASP3 BDNF ACHE ABCB1
42 hearing loss, noise-induced 30.7 TH GSTM1
43 cerebral amyloid angiopathy, cst3-related 30.7 SERPINA3 PSEN1 APP
44 focal epilepsy 30.7 MIR9-1 GRIN2B GFAP BDNF
45 central nervous system disease 30.6 SLC6A3 SERPINA3 PSEN1 NGF MIR9-1 HMOX1
46 encephalomalacia 30.6 GFAP CASP3 BDNF AIF1
47 cerebral degeneration 30.6 SERPINA3 H2AC18 GFAP APP
48 movement disease 30.6 TH SLC6A3 MIR9-1 MAOB
49 cocaine abuse 30.6 SLC6A3 NGF MAOB BDNF
50 demyelinating disease 30.5 SERPINA3 NGF MIR9-1 H2AC18 BDNF

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

MGI Mouse Phenotypes related to Toxic Encephalopathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 ABCB1 ABCG2 ACHE APP BDNF CASP3
2 homeostasis/metabolism MP:0005376 10.22 ABCB1 ABCG2 ACHE AIF1 APP BDNF
3 growth/size/body region MP:0005378 10.15 ABCB1 ACHE APP BDNF CASP3 GFAP
4 nervous system MP:0003631 10 ABCB1 ABCG2 ACHE AIF1 APP BDNF
5 muscle MP:0005369 9.86 ACHE APP CASP3 GFAP HMOX1 NGF
6 no phenotypic analysis MP:0003012 9.56 ABCB1 ACHE APP BDNF CASP3 GRIN2B
7 vision/eye MP:0005391 9.28 ABCG2 ACHE AIF1 BDNF CASP3 GFAP

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 508)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cycloserine Approved Phase 4 68-41-7 401 6234
2
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
3
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
6
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
7
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
8
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
9
Levetiracetam Approved Phase 4 102767-28-2 441341
10
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
11
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
12
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
13
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
14
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
15
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
16
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
17
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
18
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
19
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Cobicistat Approved Phase 4 1004316-88-4
22
Dolutegravir Approved Phase 4 1051375-16-6 54726191
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
27 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
28
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
29
Abatacept Approved Phase 4 332348-12-6 10237
30
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Sodium citrate Approved, Investigational Phase 4 68-04-2
33
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
35
Nalbuphine Approved Phase 4 20594-83-6 5360630 5311304
36
Acetaminophen Approved Phase 4 103-90-2 1983
37
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
38
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
39
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
40
Racepinephrine Approved Phase 4 329-65-7 838
41
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
42
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 6857599 43805
43
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
44
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
45
Bevacizumab Approved, Investigational Phase 4 216974-75-3
46
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
47
Mycophenolic acid Approved Phase 4 24280-93-1 446541
48
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
49
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
50
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380

Interventional clinical trials:

(show top 50) (show all 466)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
3 Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial> Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
4 Remifentanil-dexmedetomidine Anesthesia as an Alternative Anesthetic for Elective Pediatric Surgery: a Pilot Study. Unknown status NCT02799589 Phase 4 Remifentanil;Dexmedetomidine;Ropivacaine
5 The Optimal Dose Of Dexamethasone To Be Used As An Adjuvant To Low Volume Bupivacaine Ultrasound Guided Supraclavicular Brachial Plexus Block. A Randomized Controlled Double Blinded Dose Ranging Study Unknown status NCT03043495 Phase 4 Dexamethasone
6 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
7 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Completed NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
8 Thermal Quantitative Sensory Testing as a Method to Semi-quantitatively Assess the Neurosensory Effects of 3 Local Anesthetic Solutions in an Interscalene Block Completed NCT02271867 Phase 4
9 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
10 Effects of Peri-neural Dexmedetomidine on the Pharmacodynamic Profile of Bupivacaine-induced Adductor Canal Block in Patients Undergoing Arthroscopic Medial Meniscectomy Completed NCT03030950 Phase 4 Dexmedetomidine;Normal saline
11 Interventional Multicentre Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Completed NCT03076151 Phase 4 Tacrolimus monohydrate (ADOPORT®)
12 Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression Completed NCT00306397 Phase 4 Rapamycin
13 Phase IV Study of Cognitive and Behavioral Effects of Lacosamide as Adjunctive Therapy in Patients With Partial Epilepsy Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
14 Double Blinded Randomized Controlled Study Evaluating the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block in Patients Undergoing Ambulatory Shoulder Surgery Completed NCT02653144 Phase 4 Ropivacaine;Dexmedetomidine;Dexamethasone
15 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
16 Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy Completed NCT01641172 Phase 4
17 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
18 A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy. Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
19 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment. Completed NCT01372904 Phase 4 Dexamethasone Phosphate
20 Steroid Free Immunosuppression in Liver Transplantation Completed NCT00296244 Phase 4 Steroids;Basiliximab;Tacrolimus;Enteric-coated Mycophenolic acid (EC-MPA)
21 Adductor Canal Block: Single Injection vs Catheter for Pain Management of Total Knee Arthroplasty - A Randomized, Unblinded, Non-Inferiority Trial Completed NCT02798835 Phase 4 Adductor canal block;Adductor canal block with dexamethasone;Adductor canal catheter;Bupivacaine;Fentanyl;Ropivacaine 0.5% Injectable Solution;Dexamethasone
22 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
23 Phase IV, Open Label, Randomized, Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir Alafenamide/Emtricitabine/Darunavir/Cobicistat Recruiting NCT03685500 Phase 4 Symtuza® (TAF/FTC/DRV/c);ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
24 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
25 MARaviroc-based Treatment Switch in HIV-positive Patients With HAND: Consequences of Reducing Antiretroviral-associated Neurotoxicity Recruiting NCT03163277 Phase 4 emtricitabine, darunavir/cobicistat, maraviroc
26 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Recruiting NCT02334722 Phase 4 Levetiracetam extended release
27 Impact of Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block on Postoperative Delirium and Long-term Oucomes in Elderly Patients After Single Knee Arthroplasty Recruiting NCT03629483 Phase 4 Dexmedetomidine;Placebo
28 Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA Recruiting NCT02213068 Phase 4 belatacept;Tacrolimus;MPA
29 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
30 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
31 The Effect of Conversion to Once-Daily Envarsus® on the Neurologic Toxicity Burden in Liver Transplant Recipients Not yet recruiting NCT03823768 Phase 4 Envarsus;Tacrolimus Immediate release
32 Comparison of Ropivacaine With or Without Fentanyl in Spinal Anaesthesia for Lower Limb Surgeries Not yet recruiting NCT04199013 Phase 4 Ropivacaine 0.75% Injectable Solution;Fentanyl Citrate
33 Comparison of Analgesic Efficacy of Two Different Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia: Randomized Clinical Trial. Not yet recruiting NCT03399474 Phase 4 Dexmedetomidine Injection 0.25 ug/kg;Lidocaine;Nalbuphine;Paracetamol;Diclofenac sodium (Voltaren®);Dexmedetomidine Injection 0.5ug/kg
34 Comparison of Periosteal and Subcutaneous Infusions of Articaine and Bupivacaine in Treatment of Acute Pain After Sternotomy Suspended NCT01536717 Phase 4 Articaine hydrochloride 2% solution;Sodium Chloride
35 Pilot Study of L-Carnitine Supplementation in the Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
36 A Prospective Randomized Trial of Prednisone and Tacrolimus Versus Prednisone, Tacrolimus and Mycophenolate Mofetil in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
37 CONCEPT - Phase IV, Randomized, Prospective, Multicenter Comparison of Intermittent Schedule of Oxaliplatin Combined With FOLFOX/Bevacizumab vs Conventional Mode of Administration of FOLFOX/Bevacizumab + Neuroprophylaxis With Calcium/Magnesium for Optimization of First-Line Therapy of Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
38 Pain Management After Total Shoulder Arthroplasty: Continuous Interscalene Block Versus Local Tissue Infiltration With Liposomal Bupivacaine Terminated NCT03219983 Phase 4 Ropivacaine;liposomal bupivacaine
39 The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Gastric Cancer Unknown status NCT02024438 Phase 3 monosialotetrahexosylganglioside Sodium
40 The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Colorectal Cancer Unknown status NCT02024412 Phase 3 monosialotetrahexosylganglioside Sodium
41 A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients. Unknown status NCT01882621 Phase 3 Monosialoganglioside(GM1);normal saline
42 Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study Unknown status NCT02084355 Phase 3 oral oxycodone;oral hydromorphone;fentanyl patch
43 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
44 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Unknown status NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
45 The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients. Randomized Trial Unknown status NCT02024191 Phase 3
46 Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study Unknown status NCT00660842 Phase 3 paclitaxel;carboplatin;paclitaxel
47 A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
48 A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT02043288 Phase 3 NC-6004;Gemcitabine
49 CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study Unknown status NCT00054184 Phase 3 docetaxel;paclitaxel poliglumex
50 Phase III Italian Multicenter Study Comparing the Combination of 5-fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan (Folfoxiri) Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer Unknown status NCT02355119 Phase 3 FOLFOXIRI;Gemcitabine

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

40
Brain, Breast, Liver, Lung, T Cells, Colon, B Cells

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 415)
# Title Authors PMID Year
1
Wernicke encephalopathy associated with hyperemesis gravidarum. 61
31784394 2019
2
Short-Course Self-Medication of Metronidazole Leading to Acute Toxic Encephalopathy and Ataxia. 61
31736605 2019
3
[Analysis of 18 cases of toxic encephalopathy caused by occupational acute 1, 2-dichloroethane poisoning]. 61
31726511 2019
4
Roles of neuroimage in toxic encephalopathy induced by 1, 2-Dichloroethane. 61
31319235 2019
5
Diagnosing solvent-induced chronic toxic encephalopathy: the effect of underperformance in neuropsychological testing. 61
31082289 2019
6
Cephalosporin-related neurotoxicity: Metabolic encephalopathy or non-convulsive status epilepticus? 61
31201049 2019
7
Neurologic Acyclovir Toxicity in the Absence of Kidney Injury. 61
31171414 2019
8
Baclofen Neurotoxicity: A Metabolic Encephalopathy Susceptible to Exacerbation by Benzodiazepine Therapy. 61
30688773 2019
9
Methadone-induced Toxic Encephalopathy In Pediatric Patients: Two Case Reports. 61
31558953 2019
10
The clinical and pathological features of toxic encephalopathy caused by occupational 1,2-dichloroethane exposure. 61
31027082 2019
11
Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment. 61
29121830 2019
12
Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin's Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®). 61
31016071 2019
13
Successful treatment of a patient with severe thallium poisoning in a coma using Prussian blue and plasma exchange: A case report. 61
30813198 2019
14
[Characteristics of clinical, Magnetic Resonance Imaging and electroencephalogram after trimethyltin chloride poisoning]. 61
30929356 2019
15
Epileptic seizures and occupational exposure to solvents: a cases series. 61
30794249 2019
16
Human adenovirus type 7 infection causes a more severe disease than type 3. 61
30626350 2019
17
Therapeutic Potential of Citronella Essential Oil: A Review. 61
30019646 2019
18
Acute toxic encephalopathy induced by occupational exposure to 1,2-dichloropropane. 61
29973469 2018
19
1,2-Dichloroethane-induced hepatotoxicity and apoptosis by inhibition of ERK 1/2 pathways. 61
29852074 2018
20
Quantification of hypoglycin A and methylenecyclopropylglycine in human plasma by HPLC-MS/MS. 61
30056267 2018
21
Imaging the Unconscious "Found Down" Patient in the Emergency Department. 61
30007754 2018
22
Cuban Epidemic Neuropathy: Insights into the Toxic-Nutritional Hypothesis through International Collaboration. 61
29773773 2018
23
An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. 61
28748330 2018
24
An aggravated return-to-work case of organic solvent induced chronic toxic encephalopathy. 61
29719722 2018
25
[M'khinza-related intoxication: about two observations]. 61
30918546 2018
26
A Novel Mutation of Beta-ketothiolase Deficiency: The First Report from Iran and Review of Literature. 61
30026775 2018
27
REYE (RAY'S) SYNDROME: A PROBLEM EVERYONE SHOULD REMEMBER. 61
29227269 2017
28
Survival in Out-of-hospital Rapid Sequence Intubation of Non-Traumatic Brain Pathologies. 61
28622071 2017
29
Mercury poisoning through intravenous administration: Two case reports with literature review. 61
29145289 2017
30
Gardnerella vaginalis bacteremia associated with severe acute encephalopathy in a young female patient. 61
28546029 2017
31
[Clinical effect of electroencephalographic biofeedback therapy in treatment of memory disorders in patients with acute severe toxic encephalopathy]. 61
29294552 2017
32
Routine fruit washing to prevent acute toxic encephalopathy. 61
28807178 2017
33
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. 61
28807179 2017
34
Subcortical brain atrophy in Gulf War Illness. 61
28634886 2017
35
[An investigation of an accident of occupational acute hydrogen sulfide poisoning]. 61
29081104 2017
36
Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study. 61
28153514 2017
37
Myoclonic seizure prior to diagnosis of chronic toxic encephalopathy: a case report. 61
28173825 2017
38
[ACTION OF L-CARNITINE, CORVITIN AND THEIR COMBINATION ON FUNCTIONAL STATE OF LIVER IN EXPERIMENTAL MODEL OF REYE SYNDROME IN RATS]. 61
28452736 2017
39
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. 61
27815462 2016
40
Emergency treatment and nursing of children with severe pneumonia complicated by heart failure and respiratory failure: 10 case reports. 61
27698703 2016
41
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. 61
27673102 2016
42
Marchiafava-Bignami disease in chronic alcoholic patient. 61
27594956 2016
43
[Toxic encephalopathy caused by liquefied gas exposure: Report of one case]. 61
27905657 2016
44
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. 61
26610794 2016
45
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. 61
27114653 2016
46
[The role of smoking and metabolic enzyme polymorphisms in the organic solvent induced chronic encephalopathy]. 61
27220440 2016
47
Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device. 61
27872609 2016
48
Retrospective analysis of prognostic factors in dengue infected patients with intracranial bleed. 61
28031986 2016
49
Toxic encephalopathy due to paradichlorobenzene toxicity: a case report and review of imaging characteristics. 61
26388394 2015
50
Capecitabine: toxic encephalopathy. 61
26688902 2015

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.43 TH SLC6A3 PSEN1 MIR9-1 GRIN2B CASP3
2
Show member pathways
12.61 TH SLC6A3 MAOB GRIN2B ACHE
3 12.27 TH PSEN1 NGF GRIN2B GFAP APP
4 12.01 TH NGF CASP3 BDNF
5 11.92 NGF GRIN2B CASP3 BDNF
6 11.81 GFAP CASP3 BDNF AIF1
7 11.68 TH SLC6A3 CASP3
8
Show member pathways
11.63 GSTM1 EPHX1 ABCG2
9
Show member pathways
11.63 TH SLC6A3 MAOB GRIN2B BDNF
10 11.57 EPHX1 ABCG2 ABCB1
11 11.51 HMOX1 ABCG2 ABCB1
12
Show member pathways
11.29 TH SLC6A3 ACHE
13 11.25 TH NGF GFAP BDNF ABCG2
14 11.09 TH SLC6A3 MAOB
15 10.91 HMOX1 EPHX1 ABCG2
16
Show member pathways
10.86 TH SLC6A3 MAOB
17
Show member pathways
10.84 PSEN1 NGF CASP3 BDNF APP
18 10.74 CASP3 BDNF
19 10.74 TH MAOB
20 10.66 TH ACHE
21 10.29 GSTM1 EPHX1

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.88 PSEN1 HMOX1 BDNF APP AIF1 ACHE
2 neuron projection GO:0043005 9.83 TH SLC6A3 PSEN1 GRIN2B APP
3 neuromuscular junction GO:0031594 9.65 PSEN1 APP ACHE
4 membrane raft GO:0045121 9.65 SLC6A3 PSEN1 CASP3 APP ABCG2
5 axon GO:0030424 9.63 TH SLC6A3 PSEN1 NGF BDNF APP
6 smooth endoplasmic reticulum GO:0005790 9.5 TH PSEN1 APP
7 cell surface GO:0009986 9.5 SLC6A3 PSEN1 GRIN2B APP ACHE ABCG2
8 ciliary rootlet GO:0035253 9.49 PSEN1 APP
9 astrocyte projection GO:0097449 9.46 GFAP APP
10 external side of apical plasma membrane GO:0098591 9.37 ABCG2 ABCB1
11 synaptic vesicle GO:0008021 9.02 TH PSEN1 NGF BDNF APP

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.88 TH SLC6A3 MAOB CASP3 ABCB1
2 negative regulation of neuron apoptotic process GO:0043524 9.85 PSEN1 NGF HMOX1 BDNF
3 locomotory behavior GO:0007626 9.83 TH SLC6A3 APP
4 modulation of chemical synaptic transmission GO:0050804 9.82 NGF GRIN2B BDNF
5 response to wounding GO:0009611 9.81 GFAP CASP3 ACHE
6 response to organic cyclic compound GO:0014070 9.73 TH SLC6A3 EPHX1 CASP3
7 neuron apoptotic process GO:0051402 9.71 PSEN1 CASP3 APP
8 response to ethanol GO:0045471 9.71 TH SLC6A3 MAOB GRIN2B
9 nerve growth factor signaling pathway GO:0038180 9.65 NGF BDNF
10 positive regulation of chemokine biosynthetic process GO:0045080 9.64 HMOX1 APP
11 amyloid precursor protein metabolic process GO:0042982 9.64 PSEN1 ACHE
12 neuron projection maintenance GO:1990535 9.63 PSEN1 APP
13 dopamine biosynthetic process GO:0042416 9.62 TH SLC6A3
14 neurotransmitter catabolic process GO:0042135 9.62 MAOB ACHE
15 memory GO:0007613 9.62 TH PSEN1 NGF BDNF
16 modulation of age-related behavioral decline GO:0090647 9.61 PSEN1 APP
17 cellular response to manganese ion GO:0071287 9.61 TH APP
18 dopamine catabolic process GO:0042420 9.6 SLC6A3 MAOB
19 positive regulation of collateral sprouting GO:0048672 9.59 NGF BDNF
20 mating behavior GO:0007617 9.58 TH APP
21 transepithelial transport GO:0070633 9.58 ABCG2 ABCB1
22 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.57 PSEN1 APP
23 export across plasma membrane GO:0140115 9.56 ABCG2 ABCB1
24 positive regulation of amyloid fibril formation GO:1905908 9.52 PSEN1 APP
25 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.51 PSEN1 APP
26 astrocyte activation involved in immune response GO:0002265 9.49 PSEN1 APP
27 drug transport across blood-brain barrier GO:1990962 9.46 ABCG2 ABCB1
28 neurotrophin TRK receptor signaling pathway GO:0048011 9.43 NGF CASP3 BDNF
29 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.37 PSEN1 APP
30 neurotransmitter biosynthetic process GO:0042136 9.33 TH SLC6A3 ACHE
31 learning or memory GO:0007611 9.26 PSEN1 GRIN2B CASP3 APP
32 response to nicotine GO:0035094 8.92 TH SLC6A3 HMOX1 CASP3

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 xenobiotic transmembrane transporter activity GO:0042910 9.26 ABCG2 ABCB1
2 dopamine binding GO:0035240 9.16 TH SLC6A3
3 efflux transmembrane transporter activity GO:0015562 8.96 ABCG2 ABCB1
4 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.62 ABCG2 ABCB1

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....